Publications by authors named "J Wuerfel"
Background And Objectives: Early treatment of multiple sclerosis (MS) reduces disease activity and the risk of long-term disease progression. Effectiveness of ocrelizumab is established in relapsing MS (RMS); however, data in early RMS are lacking. We evaluated the 4-year effectiveness and safety of ocrelizumab as a first-line therapy in treatment-naive patients with recently diagnosed relapsing-remitting MS (RRMS).
View Article and Find Full Text PDFArticle Synopsis
- Patients with neuromyelitis optica spectrum disorder (NMOSD) often have antibodies against aquaporin-4 (AQP4), making MRI monitoring critical for understanding the disease's progression.
- A retrospective study involved MRI data from 525 AQP4-IgG-seropositive NMOSD patients across 11 countries, focusing on the types and locations of lesions in the central nervous system.
- Results showed a high prevalence of hyperintense lesions in the brain and significant patterns of myelitis in the spinal cord, emphasizing the importance of MRI in tracking this condition.
Background: Atrial fibrillation is a major risk factor for stroke and silent brain infarcts. We studied whether a multimodal approach offers additional insights to the CHADS-VASc score in predicting stroke or new brain infarcts on magnetic resonance imaging (MRI) over a 2-year follow-up.
Methods: Swiss-AF is a prospective, multicenter cohort study of patients with known atrial fibrillation.
Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that produces acute, unpredictable relapses causing cumulative neurological disability. Satralizumab, a humanized, monoclonal recycling antibody that targets the interleukin-6 receptor, reduced NMOSD relapse risk vs. placebo in two Phase 3 trials: SAkuraSky (satralizumab ± immunosuppressive therapy; NCT02028884) and SAkuraStar (satralizumab monotherapy; NCT02073279).
View Article and Find Full Text PDFBackground: Detecting new and enlarged lesions in multiple sclerosis (MS) patients is needed to determine their disease activity. LeMan-PV is a software embedded in the scanner reconstruction system of one vendor, which automatically assesses new and enlarged white matter lesions (NELs) in the follow-up of MS patients; however, multicenter validation studies are lacking.
Purpose: To assess the accuracy of LeMan-PV for the longitudinal detection NEL white-matter MS lesions in a multicenter clinical setting.